



Consumer, Brands & Retail

Dow Jones: 25,745.67 (10.37% ytd) | CAC40: 5382.66 (13.78% ytd) | Stoxx 600: 380.84(12.79% ytd)

22nd March 2019

Please find our Research on Bloomberg BRYG <GO>

RICHEMONT | BUY | CHF87 vs. CHF92

Investments in Cartier should weigh on EBIT margin
FY sales 2018/19 expected to grow 8%
Strong investments expected in Cartier
2018/19 EBIT revised down by 4%
New FV at CHF87 vs CHF92

Fashion & E-Commerce |

Solid Q3 results despite US sales miss
Q3 Sales in line despite US sales miss
Q3 EPS came in at 68¢, beating analysts' 65¢ estimate
No surprise to FY19 and FY20 outlook
NKE currently leads the race... but ADS is not far behind

Upcoming BG events :

Date

3rd-Apr CAPGEMINI | Luxembourg roadshow with CFO / IR
30th-Apr BIOCARTIS | London roadshow with CEO/IR

Recent reports :

Date

19th-Mar SemiConductors | @BG Technology Conference 2019
18th-Mar ONCODESIGN | Planets are aligning
12th-Mar BLUELINEA | The Silver Economy: a golden opportunity!
12th-Mar MEDINCELL | Injecting more value
12th-Mar BLUELINEA | La Silver Economie : un marché en OR !
6th-Mar AB INBEV | Battle for the Middle Kingdom

Q1 2019 Top Picks

SANOFI (Buy, FV EUR94)
NOVARTIS (Buy, FV CHF96)
ROCHE HOLDING (Buy, FV CHF315)
GALAPAGOS (Buy, FV EUR125)

RICHEMONT

Consumer, Brands & Retail
| Luxury Goods

22nd March 2019

BUY

Fair Value CHF87 vs. CHF92 (+20%)
Share price CHF72.22
EPS 3Y Cagr 17.5%

Investments in Cartier should weigh on EBIT margin

FY sales 2018/19 expected to grow 8%

We expect FY 2018/19 (March 2019) sales to grow 8% organically (o/w +10% for Jewellery Maisons) to EUR13.84bn, implying +12% in Q4 alone given a very undemanding comparison basis. Q4 2017/18 sales were impacted by inventories, watches, and a buyback in the “Specialists watches” division (EUR200m). Nevertheless, the watches business (37% of CFR sales) remains one of the most challenging in the global luxury goods industry, as highlighted by relatively poor figures of the Swiss watches exports (+2% YTD after +3% in H2 2018), even if the high-end segment (above CHF 3000) clearly outperforms (+6% YTD after +4% in H2 2018) the whole industry. On the other hand, the jewellery industry (36% of CFR sales) is much better oriented (+15% for Richemont in H1 2018 vs +5% for watches), partly thanks to an increasingly branded market, especially for the high-end segment.

Strong investments expected in Cartier

Recently, Cyrille Vigneron, CEO of Cartier since 2016, acknowledged that in some stores, the shopping experience was below what consumer could expect and that some adjustments were necessary. Actually, some stores are under renovation and refurbishment, which entails closure in some cases. This added to the costs linked to renovations should lead in H2 and also in 2019/20 to some pressure on EBIT margin. At year-end 2018, Cartier operated some 202 Directly Operated stores (DOS), combined with 72 franchised stores. We estimate Cartier sales at around EUR5.3bn o/w EUR1.4bn for watches (close to 400,000 units sold per year). This brand is quite exposed to millennials (45% of sales). Furthermore, a new jewellery line should be launched in Q1 2019/20 with some costs (mainly A&P) already affected Q4 2018/19. On the other hand, the 90 DOS of **Van Cleef & Arpels** (sales estimated at EUR1.5bn) do not need the same work. Therefore, we estimate that the 2018/19 EBIT margin of the “*Jewellery Maisons*” business should be limited at 32% (32.8% previously) versus 29.9% a year ago, implying in H2 a gain of only 150bp after +280bp in H1.

2018/19 EBIT revised down by 4%

Furthermore, we are also more cautious on profitability for the “*Specialists Watches*” business in terms of EBIT margin (14.8% vs 16% previously) given the strategy to optimize the wholesale network which accounts for 70% of the sales of this division. We recall investors that “*online distributors*” EBIT will reach EUR-235m, partly due to impairments following YNAP acquisition. Consequently, we revise down our 2018/19 EBIT estimates for Richemont by 4% with a 2018/19 EBIT margin at 15% (15.9% previously expected), down 180bp vs 2017/18.

New FV at CHF87 vs CHF92

We remain at Buy on the stock, but we lower our FV from CHF92 to CHF87 following our earnings adjustments. We still favour LVMH and Kering in our luxury sample.

Market Data

Bloomberg / Reuters	CFR VX/CFR.VX
Market Cap.	CHF37,699m
E.V.	CHF28.111m
Free Float	50
Avg. Daily volume (6m)	1,904
12m high / low	99.0 / 60.9
Ytd Perf.	14.6%

EURM	03/17	03/18e	03/19e	03/20e
Sales	10,979	13,845	14,615	15,465
% Change		26.1%	5.6%	5.8%
EBITDA	2,254	2,525	2,830	3,105
% Change		12.0%	12.1%	9.7%
EBIT	2,007	2,080	2,380	2,685
% Change		3.6%	14.4%	12.8%
Net Income	1,221	1,500	1,746	1,980
% Change		22.9%	16.4%	13.4%
ROE	0.08	0.11	0.12	0.13

	03/17	03/18e	03/19e	03/20e
EV/Sales	2.6x	2.2x	2.0x	1.9x
EV/EBITDA	12.5x	12.0x	10.6x	9.5x
EV/EBIT	14.0x	14.5x	12.6x	11.0x
EPS	2.18	2.68	3.12	3.54
% change		22.9%	16.4%	13.4%
P/E	29.4x	23.9x	20.5x	18.1x
Div Yield	3.0%	3.1%	3.4%	3.6%

Next Catalyst : FY results to be reported on May 17th

Last rating Change:

2016-9-14, 13% sales decline in first 5m

Last FV Change:

2018-11-12, 2018-2020 EPS revised down by 7%

Last Reports:

2019-1-11, Slightly disappointing Q3 figures

Loïc Morvan

33(0) 1 70 36 57 24

lmorvan@bryangarnier.com

[Click here to download](#)

RICHEMONT

BUY

Fair Value CHF87 vs. CHF92
(+20%)

Share price CHF72.22

Market Cap. CHF37,699m

EPS 3Y 17.5%

CAGR

Income Statement (EURm)		2016	2017	2018e	2019e	2020e
Revenues		10,647	10,979	13,845	14,615	15,465
<i>Change (%)</i>		-3.9%	3.1%	26.1%	5.6%	5.8%
Gross margin		6,799	7,150	8,670	9,220	9,850
<i>Change (%)</i>		-4.5%	5.2%	21.3%	6.3%	6.8%
EBITDA		2,174	2,254	2,525	2,830	3,105
EBIT		1,764	2,007	2,080	2,380	2,685
<i>Change (%)</i>		-14.4%	13.8%	3.6%	14.4%	12.8%
Financial results		-160	-150	-120	-100	-85
Pre-Tax profits		1,604	1,857	1,960	2,280	2,600
Exceptionals		3	4	5	6	7
Tax		360	432	495	575	630
Profits from associates		-34	-41	0	1	0
Minority interests		3	4	5	6	7
Net profit		1,210	1,221	1,500	1,746	1,980
Restated net profit		1,210	1,221	1,500	1,746	1,980
<i>Change (%)</i>		-28.3%	0.9%	22.9%	16.4%	13.4%
Cash Flow Statement (EURm)						
Operating cash flows		1,619	1,781	1,959	2,155	2,370
Change in working capital		-50	-486	100	291	310
Capex, net		550	487	500	550	620
Financial investments, net		0	957	2,500	0	0
Dividends		878	918	925	1,018	1,119
Other		-215	425	0	0	0
Net debt		-5,795	-5,271	-3,203	-3,499	-3,821
Free Cash flow		1,119	1,780	1,359	1,314	1,440
Balance sheet (EURm)						
Tangible fixed assets		2,558	2,325	2,665	3,055	3,515
Intangibles assets		689	667	781	781	781
Cash & equivalents		7,931	13,458	11,392	11,688	12,010
current assets		6,502	6,126	6,324	6,754	7,213
Other assets		2,480	2,982	2,982	2,982	2,982
Total assets		20,160	25,558	24,144	25,260	26,501
L & ST Debt		2,140	8,189	8,189	8,189	8,189
Others liabilities		2,491	2,731	2,829	2,968	3,117
Shareholders' funds		15,529	14,638	13,126	14,103	15,195
Total Liabilities		20,160	25,558	24,144	25,260	26,501
Capital employed		8,037	7,296	7,850	8,531	9,301
Financial Ratios						
Gross margin		63.9%	65.1%	62.6%	63.1%	63.7%
Operating margin		16.6%	18.3%	15.0%	16.3%	17.4%
Tax rate		22.4%	25.5%	24.8%	24.8%	24.1%
Net margin		11.4%	11.1%	10.8%	11.9%	12.8%
ROE (after tax)		7.8%	8.3%	11.4%	12.4%	13.0%
ROCE (after tax)		17.0%	18.8%	20.3%	21.3%	22.0%
Gearing		-37%	-36%	-24%	-25%	-25%
Pay out ratio		83.3%	87.1%	74.7%	70.6%	65.1%
Number of shares, diluted		560,000	560,000	560,000	560,000	560,000
Data per Share (EUR)						
EPS		2.16	2.18	2.68	3.12	3.54
Restated EPS		2.16	2.18	2.68	3.12	3.54
<i>% change</i>		-28.3%	0.9%	22.9%	16.4%	13.4%
BVPS		27.73	26.14	23.44	25.18	27.13
Operating cash flows		2.89	3.18	3.50	3.85	4.23
FCF		2.00	3.18	2.43	2.35	2.57
Net dividend		1.80	1.90	2.00	2.20	2.30

Source: Company Data; Bryan, Garnier & Co ests.

Fashion & E-Commerce

Consumer, Brands & Retail

Solid Q3 results despite US sales miss

Q3 Sales in line despite US sales miss

Revenue for Q3 ended February came in at USD9.6bn (+7% reported and +11% FX-n), roughly in line with CS forecasts (USD9.65bn), having beaten expectations for six consecutive quarters. NIKE brand soared by 12% FX-n (Q2: +14% / H1: +12%), with digital sales surging 36%, whilst **Converse** missed expectations with -2% (+6% in Q2 and H1) due to weak trends in the US and Europe.

In Q3 alone for the NIKE brand: **North America** “only” grew by 7% (Q2: +9% FX-n / H1: +7%), shy of CS forecasts at -8-9%, but we recall that many retailers pointed out particularly weak sell-out trends in February. Sales in **Western Europe** increased 12% (Q2: +14% / H1: +11%) on top of a challenging macro environment in some key markets (i.e. the UK, France especially). **Greater China** remained the fastest-growing market with 24%, even though, as seen at ADS, trends have started to normalize after a strong start to the year (Q2: +31% / H1: +26%).

Q3 EPS came in at 68¢, beating analysts’ 65¢ estimate

GM expanded 130bp to 45.1%, beating CS expectations (44.7%e) and its own guidance (“approx. +70bp”) thanks to: (i) a higher share of full-price sales (Q2 FY18 was still a bit promotional), (ii) a favorable channel-mix (NIKE Direct) and (iii) positive FX tailwinds. As in the previous quarters, NIKE continued to invest massively at the opex level (digital, DTC channels), with overhead expenses up 200bp to 23.2% whilst demand creation declined 60bp to 9%. Hence, NIKE’s EBIT margin expanded 60bp to 13.6%, slightly topping CS expectations at ~13.5%.

No surprise to FY19 and FY20 outlook

For Q4, NIKE is guiding on a HSD FX-n growth and more adverse FX headwind (-6pp vs. -4% in Q3) and a GM expansion of approx. 75bp. As a consequence, FY19 outlook is also reiterated, i.e. FX-n revenue growth landing in the HSD-low DD range and GM improvement that will beat Nike’s MT guidance (-50bp).

In our view, investors were also expecting first indications about FY20, given some major sporting events such as Tokyo 2020 Olympics and UEFA EURO 2020. Management provided with a HSD revenue growth (CS: -8%) and expects a GM improvement in line with the above-mentioned target (CS: +60bp).

NKE currently leads the race... but ADS is not far behind

Despite some profit-taking due to the US sales miss, and even if ADS and NKE stocks have both risen by 14% ytd, we believe that the current market’s positive stance in favor of NKE will remain, fueled by: (i) ADS’ supply chain issues in North America (apparel category) in H1 will certainly facilitate NKE’s market share gains, (ii) NKE’s strong innovation pipeline and (iii) Western Europe’s volatile environment which could be more harmful to ADS.

Yet, ADS is close second and remains one of the fastest-growing group in our Consumer coverage (CAGR EPS 18-21e of ~13%), driven by a -6%e in FY19 (+7-8% in H2 though) and HSD FX-n sales growth in FY20 (Greater China, US post supply chain issues, digital), a solid execution in profitability improvement and a higher shareholder return.

BG Coverage

adidas Group | BUY | EUR218
 INDITEX | BUY | EUR33
 CECONOMY | NEUTRAL | EUR6,2
 H & M | NEUTRAL | SEK175
 MAISONS DU MONDE | NEUTRAL | EUR32
 ZALANDO | NEUTRAL | EUR34

Last rating Change:

MAISONS DU MONDE - 08/11/2018
Visibility on the timing of the rebound in consumption in France is deteriorating

ZALANDO - 20/09/2018
The worst now seems to be behind us

MAISONS DU MONDE - 18/07/2018
Harder, Better, Faster, Stronger

Last FV Change:

adidas Group - 14/03/2019
Balancing earnings growth AND top line momentum

adidas Group - 14/03/2019
Balancing earnings growth AND top line momentum

MAISONS DU MONDE - 13/03/2019
Disappointing guidance for 2019 growth

ZALANDO - 01/03/2019
CMD points to an unattractive 3-year transition period

Cédric Rossi

33(0) 1 70 36 57 25
 crossi@bryangarnier.com

[Click here to download](#)

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 54.2%

NEUTRAL ratings 39%

SELL ratings 6.8%

Bryan Garnier Research Team

Healthcare	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Pharmaceuticals	Jean-Jacques Le Fur, PharmD	33 (0) 1 70 36 57 45	jjlefur@bryangarnier.com
	Biotech	Gary Waanders, PhD	44 207 332 25 45	gwaanders@bryangarnier.com
	Medtech / Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
	Biotech / Medtech	Victor Floc'h	33 (0) 1 70 36 57 01	vfloch@bryangarnier.com
	Biotech	Ross Blair, MbChB	44 207 332 25 05	rblair@bryangarnier.com
Technology	Payments, Security & Video games	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom & Media	Thomas Coudry	33 (0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Lodging & Business services	Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
	Innovative materials & Construction	Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
	Insurance & Fintech	Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
	Software & IT services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Industrial software	David Vignon	33 (0) 1 56 68 75 92	dvignon@bryangarnier.com
	Semiconductors	Frédéric Yoboué	33 (0) 1 56 68 75 64	fyoboue@bryangarnier.com
Consumer, Brands & Retail	Beverages & Cannabis	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retail & e-commerce	Clément Genelot	33 (0) 1 56 68 75 60	cgenelot@bryangarnier.com
	Luxury & Cosmetics	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	HPC & e-commerce	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
Corporate Event Manager	Julie Montel	33 (0) 1 56 68 75 46	jmontel@bryangarnier.com	
Market Data & Information Systems Manager	Eric Monnier	33 (0) 1 56 68 75 63	emonnier@bryangarnier.com	

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

DAILY EQUITY RESEARCH UPDATE
Wake-up Call

<p>London Bryan, Garnier & Co Ltd Beaufort House 15 St. Botolph Street London EC3A 7BB United Kingdom +44 207 332 2500</p>	<p>Paris Bryan, Garnier & Co Ltd 26 Avenue des Champs-Élysées 75008 Paris France +33 1 56 68 75 20</p>	<p>Munich Bryan, Garnier & Co. GmbH Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11</p>	<p>Zurich Bryan, Garnier & Co Theaterstrasse 4 8001 Zurich Switzerland +41 44 991 3300</p>	<p>New York Bryan Garnier Securities 750 Lexington Avenue 16th floor New York, NY 10022 United States +1 212 337 7000</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IMPORTANT INFORMATION

This document is classified under the FCA Handbook as being investment research (independent research). Bryan, Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan, Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan, Garnier & Co Limited is authorized and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom.

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom This Report has not been approved by Bryan, Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan, Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

This Report is based on information obtained from sources that Bryan, Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan, Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its

accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan, Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.